Active Biotech AB (publ) (ACTI.ST)
SEK 0.11
(-7.32%)
SEK 0.11
(-7.32%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 44 Million SEK | -13.73% |
| 2022 | 51 Million SEK | -10.21% |
| 2021 | 56.8 Million SEK | 76.66% |
| 2020 | 32.15 Million SEK | -51.97% |
| 2019 | 66.95 Million SEK | -77.86% |
| 2018 | 302.43 Million SEK | -0.45% |
| 2017 | 303.81 Million SEK | -26.42% |
| 2016 | 412.87 Million SEK | -8.14% |
| 2015 | 449.44 Million SEK | -37.8% |
| 2014 | 722.52 Million SEK | -5.9% |
| 2013 | 767.8 Million SEK | 10.2% |
| 2012 | 696.73 Million SEK | -18.84% |
| 2011 | 858.51 Million SEK | 70.65% |
| 2010 | 503.09 Million SEK | 0.92% |
| 2009 | 498.49 Million SEK | 5.4% |
| 2008 | 472.94 Million SEK | -3.39% |
| 2007 | 489.54 Million SEK | 5.87% |
| 2006 | 462.4 Million SEK | -18.57% |
| 2005 | 567.86 Million SEK | 81.49% |
| 2004 | 312.88 Million SEK | -9.41% |
| 2003 | 345.4 Million SEK | -26.12% |
| 2002 | 467.5 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 33.6 Million SEK | -23.64% |
| 2024 Q3 | 14.9 Million SEK | -32.58% |
| 2024 Q2 | 22.1 Million SEK | -34.23% |
| 2023 FY | 44 Million SEK | -13.73% |
| 2023 Q1 | 39.5 Million SEK | -22.56% |
| 2023 Q3 | 14.3 Million SEK | -41.87% |
| 2023 Q2 | 24.6 Million SEK | -37.72% |
| 2023 Q4 | 44 Million SEK | 207.69% |
| 2022 Q4 | 51 Million SEK | -22.25% |
| 2022 Q2 | 32.8 Million SEK | -22.46% |
| 2022 Q1 | 42.3 Million SEK | -25.53% |
| 2022 FY | 51 Million SEK | -10.21% |
| 2022 Q3 | 65.6 Million SEK | 100.0% |
| 2021 Q1 | 97.1 Million SEK | 201.97% |
| 2021 Q2 | 83 Million SEK | -14.52% |
| 2021 Q4 | 56.8 Million SEK | -21.87% |
| 2021 Q3 | 72.7 Million SEK | -12.41% |
| 2021 FY | 56.8 Million SEK | 76.66% |
| 2020 Q4 | 32.15 Million SEK | -10.68% |
| 2020 FY | 32.15 Million SEK | -51.97% |
| 2020 Q1 | 54.2 Million SEK | -19.05% |
| 2020 Q2 | 43.9 Million SEK | -19.0% |
| 2020 Q3 | 36 Million SEK | -18.0% |
| 2019 Q2 | 83.9 Million SEK | -71.43% |
| 2019 Q4 | 66.95 Million SEK | -15.14% |
| 2019 FY | 66.95 Million SEK | -77.86% |
| 2019 Q1 | 293.7 Million SEK | -2.89% |
| 2019 Q3 | 78.9 Million SEK | -5.96% |
| 2018 Q2 | 323.8 Million SEK | 11.2% |
| 2018 Q1 | 291.2 Million SEK | -4.15% |
| 2018 Q3 | 313.3 Million SEK | -3.24% |
| 2018 Q4 | 302.43 Million SEK | -3.47% |
| 2018 FY | 302.43 Million SEK | -0.45% |
| 2017 Q2 | 379.4 Million SEK | -4.6% |
| 2017 Q4 | 303.81 Million SEK | -17.04% |
| 2017 FY | 303.81 Million SEK | -26.42% |
| 2017 Q1 | 397.7 Million SEK | -3.68% |
| 2017 Q3 | 366.2 Million SEK | -3.48% |
| 2016 Q1 | 407.7 Million SEK | -9.29% |
| 2016 FY | 412.87 Million SEK | -8.14% |
| 2016 Q3 | 374.3 Million SEK | -4.95% |
| 2016 Q2 | 393.8 Million SEK | -3.41% |
| 2016 Q4 | 412.87 Million SEK | 10.31% |
| 2015 FY | 449.44 Million SEK | -37.8% |
| 2015 Q4 | 449.44 Million SEK | -13.87% |
| 2015 Q3 | 521.8 Million SEK | -9.27% |
| 2015 Q2 | 575.1 Million SEK | -12.93% |
| 2015 Q1 | 660.5 Million SEK | -8.58% |
| 2014 Q2 | 618.3 Million SEK | -10.46% |
| 2014 Q4 | 722.52 Million SEK | 31.32% |
| 2014 Q3 | 550.2 Million SEK | -11.01% |
| 2014 Q1 | 690.5 Million SEK | -10.07% |
| 2014 FY | 722.52 Million SEK | -5.9% |
| 2013 Q4 | 767.8 Million SEK | -6.01% |
| 2013 Q3 | 816.9 Million SEK | 4.92% |
| 2013 FY | 767.8 Million SEK | 10.2% |
| 2013 Q1 | 865.2 Million SEK | 24.18% |
| 2013 Q2 | 778.6 Million SEK | -10.01% |
| 2012 Q4 | 696.73 Million SEK | -0.65% |
| 2012 Q1 | 769.4 Million SEK | -10.38% |
| 2012 Q2 | 775.4 Million SEK | 0.78% |
| 2012 FY | 696.73 Million SEK | -18.84% |
| 2012 Q3 | 701.3 Million SEK | -9.56% |
| 2011 Q1 | 776.7 Million SEK | 54.38% |
| 2011 Q2 | 971.8 Million SEK | 25.12% |
| 2011 Q3 | 901.1 Million SEK | -7.28% |
| 2011 Q4 | 858.51 Million SEK | -4.73% |
| 2011 FY | 858.51 Million SEK | 70.65% |
| 2010 Q4 | 503.09 Million SEK | -1.02% |
| 2010 FY | 503.09 Million SEK | 0.92% |
| 2010 Q2 | 559.8 Million SEK | 26.25% |
| 2010 Q1 | 443.4 Million SEK | -11.05% |
| 2010 Q3 | 508.3 Million SEK | -9.2% |
| 2009 FY | 498.49 Million SEK | 5.4% |
| 2009 Q4 | 498.49 Million SEK | 0.0% |
| 2008 FY | 472.94 Million SEK | -3.39% |
| 2007 FY | 489.54 Million SEK | 5.87% |
| 2006 FY | 462.4 Million SEK | -18.57% |
| 2005 FY | 567.86 Million SEK | 81.49% |
| 2004 FY | 312.88 Million SEK | -9.41% |
| 2003 FY | 345.4 Million SEK | -26.12% |
| 2002 FY | 467.5 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | 62.854% |
| Ziccum AB (publ) | 14.97 Million SEK | -193.882% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -119.55% |
| BioArctic AB (publ) | 1.18 Billion SEK | 96.29% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | 29.461% |
| Mendus AB (publ) | 755.95 Million SEK | 94.18% |
| Genovis AB (publ.) | 288.85 Million SEK | 84.768% |
| Intervacc AB (publ) | 259.61 Million SEK | 83.052% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -4.864% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | 84.215% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | 29.206% |
| Aptahem AB (publ) | 63.02 Million SEK | 30.186% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | 91.133% |
| Kancera AB (publ) | 65.64 Million SEK | 32.971% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | 87.476% |
| Fluicell AB (publ) | 9.34 Million SEK | -371.092% |
| Saniona AB (publ) | 64.14 Million SEK | 31.403% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -30.945% |
| Biovica International AB (publ) | 131.4 Million SEK | 66.516% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | 16.958% |
| AcouSort AB (publ) | 34.51 Million SEK | -27.488% |
| Xintela AB (publ) | 18.39 Million SEK | -139.195% |
| Abliva AB (publ) | 87.49 Million SEK | 49.714% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | 94.212% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | 96.503% |
| OncoZenge AB (publ) | 20.34 Million SEK | -116.323% |
| Amniotics AB (publ) | 26.08 Million SEK | -68.673% |
| 2cureX AB (publ) | 16.62 Million SEK | -164.662% |
| CombiGene AB (publ) | 120.61 Million SEK | 63.519% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -624.041% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 97.685% |
| Camurus AB (publ) | 1.9 Billion SEK | 97.694% |
| Corline Biomedical AB | 100.1 Million SEK | 56.046% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | 75.158% |
| Isofol Medical AB (publ) | 140.59 Million SEK | 68.705% |
| I-Tech AB | 152.44 Million SEK | 71.137% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | 95.678% |
| Cyxone AB (publ) | 43.65 Million SEK | -0.79% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | 44.086% |
| Biosergen AB | 7.2 Million SEK | -511.026% |
| Cantargia AB (publ) | 223.71 Million SEK | 80.332% |
| NextCell Pharma AB | 81.28 Million SEK | 45.871% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | 94.25% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -45.826% |
| Nanologica AB (publ) | 77.42 Million SEK | 43.174% |
| SynAct Pharma AB | 228.01 Million SEK | 80.703% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -64.406% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -102.738% |
| LIDDS AB (publ) | 17.65 Million SEK | -149.221% |
| Lipum AB (publ) | 12.11 Million SEK | -263.336% |
| BioInvent International AB (publ) | 1.4 Billion SEK | 96.858% |
| Alzinova AB (publ) | 123.18 Million SEK | 64.283% |
| Oncopeptides AB (publ) | 238.37 Million SEK | 81.542% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -420.402% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | 48.373% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -195.918% |
| Simris Alg AB (publ) | 174.55 Million SEK | 74.793% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | 79.727% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | 93.267% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | 49.467% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -54.343% |